Understand the source comparison
DSIP Results After 1 Month: [Peptide] Comparison
DSIP Hypothalamic delta wave modulation 18–31% increase in Stage 3 NREM sleep duration; 8–14 minute reduction in sleep onset latency Minimal to moderate. Subjective improvements often lag 2–4 weeks behind objective changes Intranasal (20–50 mcg) or subcutaneou
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- Hypothalamic delta wave modulation
- 18–31% increase in Stage 3 NREM sleep duration; 8–14 minute reduction in sleep onset latency
- Minimal to moderate. Subjective improvements often lag 2–4 weeks behind objective changes
- Intranasal (20–50 mcg) or subcutaneous (100–500 mcg)
- Strongest objective evidence for sleep architecture improvement; weakest for immediate subjective sleep quality perception
- Epithalon
- Telomerase activation and circadian rhythm normalisation
- Circadian rhythm stabilisation; modest improvements in sleep continuity
- Moderate. Users report more consistent sleep-wake timing within 3–4 weeks
- Subcutaneous (5–10 mg per cycle)
- Better for circadian misalignment than sleep depth; works through rhythm entrainment rather than neurological sleep enhancement
- Selank
- Anxiolytic effect via GABA modulation
- Reduced sleep onset latency in anxious phenotypes; minimal delta wave change
- High. Anxiolytic effects perceived within 7–14 days in stress-related insomnia
- Intranasal (250–500 mcg)
- Effective when insomnia is anxiety-driven; does not enhance slow-wave sleep architecture like DSIP
- CJC-1295 + Ipamorelin
- Growth hormone secretion enhancement
- Increased Stage 3 and REM sleep as secondary effect of GH pulsatility
- Moderate. Improved recovery sensation reported by week 3–4
- Subcutaneous (100–200 mcg each compound)
- Sleep improvements are secondary to GH effects; not a primary sleep peptide but enhances recovery-related sleep quality